公开(公告)号：US11066470B2

公开(公告)日：2021-07-20

申请号：US16398472

申请日：2019-04-30

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nicolas Schneider

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K39/00 ,  A61K9/00

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

公开(公告)号：US12227569B2

公开(公告)日：2025-02-18

申请号：US17376314

申请日：2021-07-15

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nicolas Schneider

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  C07K16/30

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

公开(公告)号：US10280222B2

公开(公告)日：2019-05-07

申请号：US15125216

申请日：2015-03-12

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nicolas Schneider

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K39/00 ,  A61K9/00

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.